title: CD44 expression in benign and malignant nevomelanocytic lesions.
abstract: CD44 is an integral membrane glycoprotein that is a principal receptor for hyaluronan and plays a role in cell-extracellular matrix interactions. Recent studies of melanomas in mouse models have suggested that increased CD44 expression by these tumors may relate to metastatic potential. Immunohistochemical expression of CD44 (standard [s] and variant [v6]) in benign and malignant nevomelanocytic lesions was assessed in formalin-fixed, paraffin-embedded tissue and was correlated with histological parameters and prognostic factors. Cases included benign nevi (three junctional, four compound, five intradermal, five blue, six Spitz, one deep penetrating), architecturally disordered (dysplastic) nevi (three, and primary (22) and metastatic melanomas (eight). All of the benign lesions showed diffuse and essentially uniform membrane staining of CD44s in nevomelanocytic cells, regardless of lesion size, depth, or extent of dermal involvement. In contrast, semiquantitative analysis (0 to 3+) of the primary melanomas showed heterogeneous and decreased staining of CD44s, which inversely correlated with lesion size (-0.569) and depth of invasion (-0.622 and -0.617 for Breslow's depth and Clark's level, respectively). These results were significant at P < .05. CD44s expression in metastases paralleled that of their respective primaries. None of the benign nevomelanocytic lesions showed CD44v6 staining. In contrast, all of the malignant nevomelanocytic lesions showed cytoplasmic staining of the tumor cells. Pretreatment with chondroitinase did not alter CD44s staining. CD44s expression by immunohistochemical determination is uniform in benign nevomelanocytic lesions. Malignant melanomas show decreased, heterogeneous staining that inversely correlates with increasing size, depth, and level of invasion. CD44 expression may be a prognostic indicator in malignant melanomas. Tumor staining with anti-chondroitin sulfate monoclonal antibodies suggests that CD44s may be expressed as a chondroitin sulfate proteoglycan in primary melanomas.
authors.affiliation: Department of Pathology, The University of Iowa, Iowa City 52242-1009, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Leigh
authors.forename: P L
authors.initials: PL
authors.lastname: Palechek
authors.forename: J R
authors.initials: JR
authors.lastname: Knutson
authors.forename: J B
authors.initials: JB
authors.lastname: McCarthy
authors.forename: M B
authors.initials: MB
authors.lastname: Cohen
authors.forename: Z B
authors.initials: ZB
authors.lastname: Argenyi
mesh_terms: D000328:Adult; D000368:Aged; D002808:Chondroitin Lyases / Q000494:pharmacology; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009508:Nevus, Pigmented / Q000276:immunology*; D012867:Skin / Q000276:immunology
chemical_list: D018960:Hyaluronan Receptors; D002808:Chondroitin Lyases